Skip to content
  • News
  • Contacts
  • Careers
    • Work with us
    • Privacy Notice
  • Investor Relations
  •  
    • Kedrion S.p.A
    • Kedrion Biopharma GmbH
    • Kedrion Biopharma – Austria
    • Kedrion Biopharma – Portugal
    • Kedrion Biopharma – Poland
    • Kedrion Biopharma – Switzerland
    • Kedrion Biopharma – Russia
    • HUMAN Bioplazma Kft
    • Kedrion Biopharma Inc.
    • Kedrion Mexicana S.A.
    • Kedrion de Colombia
    • Kedrion Betaphar
    • KEDPLASMA USA
  •  
  •  
    • LinkedIn
  • About us
    • Annual Report
    • Corporate Social Responsibility
      • Code of Conduct
      • Environment, Health & Safety
      • Supporting our people
      • Support to communities
  • Expertise
    • Activities
    • Medical & Scientific Information
    • Research & Development
    • Quality & Safety
  • Therapies
    • Therapeutic areas
      • Rare Diseases
      • Mother and Child Health
      • Critical care and transplantation
      • Transfusion Medicine
    • Business Partners
  • Services
    • Italian partnership
    • Contract manufacturing
    • Technology transfer
    • Biological Safety Center
  • Donors
    • Plasma
  • Pharmacovigilance
kedrion logo
Find in Kedrion

Bond News

Announcement of delisting of Kedrion SpA (the “Issuer”)

Sep 01, 2022

Notice of confirmation of redemption condition of Kedrion SpA (the “Issuer”)

Sep 01, 2022

Permira Funds and the Marcucci family complete investment in Kedrion and BPL

Sep 01, 2022

Announced appointment of Ugo Di Francesco as CEO

Supplemental Notice of Redemption Price to the holders of Kedrion S.p.A (the “Issuer”)

Aug 26, 2022

Kedrion Redemption

Aug 19, 2022

Notice of conditional redemption

First Quarter 2022 Results

May 27, 2022

Kedrion recorded solid Q1 2022 performance with strong recovery in collection volumes

Annual General Meeting of Shareholders 2022

Apr 29, 2022

KEDRION ANNOUNCES EXERCISE OF EARLY REDEMPTION OF NOTES MATURING IN JULY 2022

Apr 12, 2022

Castelvecchio Pascoli, 12 April 2022 – Kedrion S.p.A. (the “Company”) announces the exercise of the residual maturity call option embedded in its €350,000,000 bond maturing on 12 July 2022 (the “Notes”) and bearing a 3.000 per cent. coupon (ISIN code: XS1645687416), of which €200,009,000 remain outstanding as of the date hereof. Pursuant to the terms

2021 Annual Results

Apr 08, 2022

SAVE THE DATE – GENERAL INVESTOR CALL

Feb 15, 2022

Posts navigation

1 2 3 … 8 Next

Kedrion

Kedrion S.p.A. with sole Shareholder
Subject to control and coordination of Kedrion Holding SpA

Sede legale: Loc. Ai Conti snc, Castelvecchio Pascoli, 55051-Barga (LU)

CF – PI Registro delle Imprese della TOSCANA NORD-OVEST N° REA LU – 01779530466
Cap. Soc. i.v. euro 60.453.901,00

HIGHLIGHTS

  • BIOSC for pathogen safety
  • Kedrion Annual Reports

USEFUL INFO

  • Credits
  • Site Map
  • Cookies
  • Terms of Use

Where We Are

© Kedrion 2022 / Kedrion S.p.A

You are now leaving the Kedrion Corporate site. The information available in your chosen website may not be in compliance with EU legislation regulating the advertising of medicinal products for human use, nor do the opinions expressed necessarily reflect the Company’s positions or are endorsed by it. In addition as per local health authority Regulations, some of our products are not approved for sales, marketing or distribution in all countries.

Kedrion logoLogo Header Menu
    • About us
      • Annual Report
      • Corporate Social Responsibility
        • Code of Conduct
        • Environment, Health & Safety
        • Supporting our people
        • Support to communities
    • Expertise
      • Activities
      • Medical & Scientific Information
      • Research & Development
      • Quality & Safety
    • Therapies
      • Therapeutic areas
        • Rare Diseases
        • Mother and Child Health
        • Critical care and transplantation
        • Transfusion Medicine
      • Business Partners
    • Services
      • Italian partnership
      • Contract manufacturing
      • Technology transfer
      • Biological Safety Center
    • Donors
      • Plasma
    • Pharmacovigilance
  • News
  • Contact
  • Careers
    • Work with us
    • Privacy Notice
  • Investor Relations
  • Kedrion’s Sites
    • Kedrion S.p.A
    • Kedrion Biopharma GmbH
    • Kedrion Biopharma – Austria
    • Kedrion Biopharma – Portugal
    • Kedrion Biopharma – Poland
    • Kedrion Biopharma – Russia
    • HUMAN Bioplazma Kft
    • Kedrion Biopharma Inc.
    • Kedrion Mexicana S.A.
    • KEDPLASMA USA
    • Kedrion Betaphar
  • Social Network
    • LinkedIn